{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lebedin M"],"funding":["European Research Council","Deutsche Forschungsgemeinschaft","Helmholtz Association of German Research Centres","EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions","BMBF Berlin","European Commission","Berlin Institute of Health at Charité"],"pagination":["109330"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10940809"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(3)"],"pubmed_abstract":["Identifying immune modulators that impact neutralizing antibody responses against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is of great relevance. We postulated that high serum concentrations of soluble angiotensin-converting enzyme 2 (sACE2) might mask the spike and interfere with antibody maturation toward the SARS-CoV-2-receptor-binding motif (RBM). We tested 717 longitudinal samples from 295 COVID-19 patients and showed a 2- to 10-fold increase of enzymatically active sACE2 (a-sACE2), with up to 1 μg/mL total sACE2 in moderate and severe patients. Fifty percent of COVID-19 sera inhibited ACE2 activity, in contrast to 1.3% of healthy donors and 4% of non-COVID-19 pneumonia patients. A mild inverse correlation of a-sACE2 with RBM-directed serum antibodies was observed. <i>In silico</i>, we show that sACE2 concentrations measured in COVID-19 sera can disrupt germinal center formation and inhibit timely production of high-affinity antibodies. We suggest that sACE2 is a biomarker for COVID-19 and that soluble receptors may contribute to immune suppression informing vaccine design."],"journal":["iScience"],"pubmed_title":["Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses."],"pmcid":["PMC10940809"],"funding_grant_id":["948464"],"pubmed_authors":["Spatt L","Garg A","Stubbemann P","de la Rosa K","Garcia CV","Obermayer B","Ratswohl C","Lebedin M","Weiner J","Thibeault C","Kurth F","Pischon T","Velasquez IM","Witzenrath M","Meyer-Hermann M","Gerhard C","Schips M","Hanitsch LG","Sander LE"],"additional_accession":[]},"is_claimable":false,"name":"Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses.","description":"Identifying immune modulators that impact neutralizing antibody responses against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is of great relevance. We postulated that high serum concentrations of soluble angiotensin-converting enzyme 2 (sACE2) might mask the spike and interfere with antibody maturation toward the SARS-CoV-2-receptor-binding motif (RBM). We tested 717 longitudinal samples from 295 COVID-19 patients and showed a 2- to 10-fold increase of enzymatically active sACE2 (a-sACE2), with up to 1 μg/mL total sACE2 in moderate and severe patients. Fifty percent of COVID-19 sera inhibited ACE2 activity, in contrast to 1.3% of healthy donors and 4% of non-COVID-19 pneumonia patients. A mild inverse correlation of a-sACE2 with RBM-directed serum antibodies was observed. <i>In silico</i>, we show that sACE2 concentrations measured in COVID-19 sera can disrupt germinal center formation and inhibit timely production of high-affinity antibodies. We suggest that sACE2 is a biomarker for COVID-19 and that soluble receptors may contribute to immune suppression informing vaccine design.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-01T03:21:29.427Z","creation":"2025-02-19T04:36:17.329Z"},"accession":"S-EPMC10940809","cross_references":{"pubmed":["38496296"],"doi":["10.1016/j.isci.2024.109330"]}}